OncoMed Pharmaceuticals Inc., a drug developer that first sold shares to the public in July, almost doubled in trading after signing a $177.25 million agreement with Celgene Corp. on as many as six potential cancer medicines.
Zebrafish experiments by Harvard University researchers yielded new chemicals that prod stem cells to make muscle tissue, an advance that may lead to treatments for muscular dystrophy and related disorders.
Cardio3 BioSciences SA, a Belgian developer of experimental stem-cell treatments, rose to the highest since its initial share sale in July after a competitor gained U.S. approval to start a trial with similar technology.
Injections of fat enriched with stem cells led to significantly higher retention of volume compared with standard procedures, according to a Danish study that may revolutionize the field of reconstructive surgery.
Six months ago, Roche Holding AG scientists disrupted the rhythmic beating of heart muscle made from stem cells by adding a cancer drug to it, duplicating in the laboratory a side effect previously only seen in patients.